India

As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.

Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

A stake acquisition in US venture Illexcor allows India's Zydus to get in on the ground floor for a potential once-daily sickle cell disease treatment. The candidate showed promising preclinical results in a field that has yielded mixed outcomes for global majors like Novartis, Pfizer and Novo Nordisk

Eyeing the lucrative opportunity, three Indian players have launched their generic versions of Boehringer’s anti-diabetes drug Jardiance in their domestic market.

Can India’s Mittelstand or small and medium enterprises win the quality game and what could help? Sectoral insights from defense and FMCG industries and from other countries like Germany might hold the key for Indian pharma, a panel of experts at a recent event opined.

Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel

Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.

Select Indian drug manufacturers have missed some analyst estimates while Japanese firms continue in their efforts to leave the country’s generic drug supply crisis in the past.

With sales remaining sluggish, on the back of fewer launches, Glenmark’s management nevertheless struck an upbeat tone when discussing the firm’s prospects in the US moving into the company’s 2026 financial year.